Citigroup analyst PJ Juvekar maintains Dow (NYSE:DOW) with a Neutral and raises the price target from $45 to $47.
Akero Therapeutics To Present Results From Phase 2b SYMMETRY Study Investigating Efruxifermin In Patients With Compensated Cirrhosis Due To NASH
Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, will hold an investor conference on
